Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Improvement of Functional Outcome for Patients With Newly Diagnosed Grade 2 or 3 Glioma With Co-deletion of 1p/19q - IMPROVE CODEL: the NOA-18 Trial

NCT05331521 is registered in ClinicalTrials.gov with University Hospital Heidelberg as lead sponsor.

NCT NCT05331521
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05331521 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Improvement of Functional Outcome for Patients With Newly Diagnosed Grade 2 or 3 Glioma With Co-deletion of 1p/19q - IMPROVE CODEL: the NOA-18 Trial
Lead sponsor
University Hospital Heidelberg
Phase
Phase 3
Overall status
Recruiting
Start date
April 7, 2021
Completion date
March 31, 2033
Enrollment
406 (estimated)
Sites
19

Conditions

As the registry lists them; a condition with its own page is linked.

oligodendroglioma